Payment overview · 2025
General Payments
$552.09
27 reported records · 10 companies
Healthcare provider profile · identity verified
Paul J Brown, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · TORRANCE, CA · NPI 1003862376
Verified facts
What the public records show
CMS Open Payments records show Paul J Brown, M.D. received $552.09 in general payments during 2025 across 27 reported records.
AstraZeneca Pharmaceuticals LP accounted for 23.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Farxiga, Mounjaro, Ozempic, Shingrix.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $129.40 | 23.4% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $102.80 | 18.6% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $83.51 | 15.1% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $54.16 | 9.8% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $53.59 | 9.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $42.02 | 7.6% | 2 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $29.71 | 5.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $24.89 | 4.5% | 1 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $17.01 | 3.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.00 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $552.09 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $83.51 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $81.60 | 5 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $76.72 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $76.72 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $76.72 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $57.21 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $53.59 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $42.02 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $42.02 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $32.61 | 2 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $29.71 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $26.08 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $26.08 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $24.89 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $24.89 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.82 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.82 | 1 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $17.01 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $17.01 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $17.01 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.19 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 40 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 98 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 58 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 26 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
58 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
26 | 21 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
60 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
40 | 40 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
98 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 433 | 129 |
| Amlodipine Besylate | Amlodipine Besylate | 294 | 91 |
| Losartan Potassium | Losartan Potassium | 280 | 75 |
| Levothyroxine Sodium | Levothyroxine Sodium | 218 | 61 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 192 | 67 |
| Lisinopril | Lisinopril | 155 | 44 |
| Pravastatin Sodium | Pravastatin Sodium | 138 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 136 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 129 | 44 |
| Simvastatin | Simvastatin | 115 | 30 |
| Gabapentin | Gabapentin | 113 | 38 |
| Lorazepam | Lorazepam | 112 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 108 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 104 | 31 |
| Furosemide | Furosemide | 102 | 30 |
| Allopurinol | Allopurinol | 99 | 24 |
| Omeprazole | Omeprazole | 99 | 32 |
| Eliquis | Apixaban | 98 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 92 | 42 |
| Ezetimibe | Ezetimibe | 89 | 31 |
| Carvedilol | Carvedilol | 87 | 23 |
| Metformin Hcl Er | Metformin Hcl | 87 | 27 |
| Trazodone Hcl | Trazodone Hcl | 86 | 27 |
| Metformin Hcl | Metformin Hcl | 84 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 83 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 81 | 18 |
| Alprazolam | Alprazolam | 73 | 14 |
| Donepezil Hcl | Donepezil Hcl | 72 | 27 |
| Atenolol | Atenolol | 69 | 21 |
| Finasteride | Finasteride | 68 | 21 |
| Meloxicam | Meloxicam | 67 | 23 |
| Bupropion Xl | Bupropion Hcl | 60 | 11 |
| Jardiance | Empagliflozin | 60 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 60 | 38 |
| Azithromycin | Azithromycin | 59 | 50 |
| Farxiga | Dapagliflozin Propanediol | 58 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 58 | 19 |
| Celecoxib | Celecoxib | 57 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 18 |
| Memantine Hcl | Memantine Hcl | 54 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 54 | 14 |
| Benazepril Hcl | Benazepril Hcl | 53 | 18 |
| Spironolactone | Spironolactone | 53 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 53 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 51 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 50 | 13 |
| Mounjaro | Tirzepatide | 50 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 50 | 16 |
| Famotidine | Famotidine | 49 | 19 |
| Ozempic | Semaglutide | 49 | suppressed |
| Mirtazapine | Mirtazapine | 48 | 14 |
| Baclofen | Baclofen | 47 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 46 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 43 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 42 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 40 | 40 |
| Pioglitazone Hcl | Pioglitazone Hcl | 37 | 11 |
| Sildenafil Citrate | Sildenafil Citrate | 36 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 34 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 34 | 16 |
| Montelukast Sodium | Montelukast Sodium | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Ketoconazole | Ketoconazole | 28 | 17 |
| Temazepam | Temazepam | 27 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 26 | 13 |
| Potassium Chloride | Potassium Chloride | 26 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 26 | 21 |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 25 | 21 |
| Dutasteride | Dutasteride | 25 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Repatha Syringe | Evolocumab | 24 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 20 |
| Testosterone | Testosterone | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Repaglinide | Repaglinide | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 12 |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Gemtesa | Vibegron | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Klor-Con 10 | Potassium Chloride | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 11 |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 14 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Diovan | Valsartan | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 12 |
| Naproxen | Naproxen | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Pentoxifylline | Pentoxifylline | 13 | suppressed |
| Ramelteon | Ramelteon | 13 | suppressed |
| Zestoretic | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Cephalexin | Cephalexin | 12 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Pristiq | Desvenlafaxine Succinate | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Tadalafil | Tadalafil | 11 | suppressed |
| Wegovy | Semaglutide | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $552.09 · 27 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AREXVY, Auvelity, BREZTRI, COMIRNATY, ELIQUIS, FARXIGA, GLYCATE, ImmunoCAP, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, RELTONE 200 MG, RELTONE 400 MG, REPATHA, Rybelsus, SHINGRIX, The Cologuard Plus Collection Kit, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error